Designed for professionals at all levels to learn about Health Economic & Outcomes Research (HEOR) concepts and trends. Select relevant modules for your team, which can also be combined with customized in-person programs.
Empower your team with interactive online training
- Engage colleagues in HEOR discussions
- Interpret HEOR studies
- Communicate HEOR data more effectively
- Understand how analyses are used by decision makers
- Become better consumers of pharmacoeconomic literature
Modules
- Define pharmacoeconomic research, and how it's used
- Identify five ways a medication can be considered "cost-effective”
- Distinguish among types of costs (direct medical, direct non-medical, indirect, intangible)
- Describe types of outcomes (e.g., surrogate vs final; economic, clinical, patient-reported) and how they are incorporated into cost-effectiveness analyses
- Recognize how to interpret a cost-effectiveness plane
- Describe various study perspectives
- Identify the importance of sensitivity analysis
- Identify differences among various pharmacoeconomic methodologies, such as cost-of-illness analysis, cost-minimization analysis, cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis
- Calculate the incremental cost-effectiveness for one medication over another
- Describe how utility values are used to calculate a quality-adjusted life year
- Explain how to interpret data plotted on a cost-effectiveness grid
- Discuss the difference between average cost-effectiveness ratios and incremental cost-effectiveness ratios
- Describe the advantages of using cost-effectiveness acceptability curves
- Define patient-reported outcomes (PROs) and when they should be used
- Identify types of instruments used to measure PROs, including generic and disease-specific tools
- Describe examples of commonly used PRO instruments, including the SF-36 Health Survey and the EQ-5D
- Discuss the importance of measuring what is important to the patient
- List examples of PRO label claims
- Outline recommendations in the FDA PRO Guidance
- Explain how a PRO instrument can be considered valid and reliable
- Identify additional resources for PRO assessments
- Explain the role of patient-reported outcomes assessment in the evaluation of health care products and services
Overview of Real-World Evidence
- Clarify definitions and policy issues, and why RWE has received so much attention from various stakeholders
- Define and distinguish between real-world-data (RWD) and real-world evidence (RWE)
- Describe different types of RWE studies including associated advantages and disadvantages
- Differentiate observational study designs including cohort, case control, and pragmatic trials
- Discuss statistical techniques used in observational research such as propensity score matching and multi-level modeling
- Compare and contrast various tools available for evaluating observational studies
Data Sources and Use in Real-World Studies
- Outline definitions and uses of primary, secondary, and tertiary data sources.
- Describe common sources and examples of observational data (registries, surveys, administrative claims and electronic medical records databases) used to generate RWE, including their advantages and limitations
- Identify common sources and examples of costs and outcomes data used to populate pharmacoeconomic analyses, including their advantages and limitations
Pay for Performance Measures (risk-based contracting)
- Define performance-based risk-sharing agreements and why they are becoming so popular
- Describe key characteristics of performance-based risk-sharing (PBRS) agreements
- Discuss use of agreements in the US, including types and therapeutic areas
- Identify good practice recommendations issued by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) PBRS Task Force
- Outline specific examples of performance-based risk-sharing (PBRS) agreements
- List benefits, challenges, and potential barriers for performance-based risk-sharing agreements
- Define components included in budget impact analyses
- Discuss ISPOR Principles of Good Practice for Budget Impact Analysis
- Describe examples of published budget impact analyses
- Identify key questions that are raised about budget impact analyses
- Outline differences between budget impact and pharmacoeconomic analyses
- Discuss ways to best communicate budget impact models with end users
- Identify the steps in building a decision tree
- Indicate how the data elements entered into a decision tree should be analyzed
- Apply the fundamental concepts learned to build a decision tree using Excel software
- Outline results from a case study on a cost-effectiveness plane
- Interpret findings from the decision analysis based on willingness-to-pay principles
- Recognize how to calculate incremental cost-effectiveness ratios (ICERs) for 3+ alternatives
- Differentiate between decision trees and Markov models
- Describe Markov model structures & how patients transition between health states
- Identify temporary, tunneling, and absorbing states in a model
- Discuss how to assign costs & utility values to health states that patients accrue over time
- Distinguish between a cohort model and a patient-level model
- Apply Markov modeling concepts to construct a model using Excel software
- Define value frameworks & identify their limitations
- Recognize that high drug prices demand justification from payers
- Outline initiatives by professional societies to create value frameworks
- Recognize the impact of the Institute for Clinical & Economic Review (ICER) recommendations
- Describe pricing strategies & alternative payment models to manage costly pharmaceuticals
- Indicate challenges with current value-based pricing models
Each Module Contains
- Learning objectives
- One-hour videos presented in approximately 15-minute segments
- Interactive video questions
- PDF handout of the presentation slides
- Self-assessment questions
- Interactive games
Pharmacy continuing education credit is not available for the online modules at this time.
For more information
 |
Lynne Mascarella, MEd |